Medical Imaging Endoscopy Equipment Ultra Sound

PUBLISHER: 360iResearch | PRODUCT CODE: 2085498

PUBLISHER: 360iResearch | PRODUCT CODE: 2085498

Endoscopy Ultrasound Market by Product, Technology, Application, End User - Global Forecast 2026-2032

PUBLISHED: July 10, 2026

PAGES: 187 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Endoscopy Ultrasound Market is projected to grow by USD 2.08 billion at a CAGR of 8.01% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.21 billion
Estimated Year [2026]	USD 1.31 billion
Forecast Year [2032]	USD 2.08 billion
CAGR (%)	8.01%

Endoscopy Ultrasound Market Introduction

Endoscopy ultrasound, commonly known as endoscopic ultrasound or EUS, combines high-frequency ultrasound imaging with endoscopic visualization to assess gastrointestinal and pancreatobiliary disease from inside the digestive tract. Its clinical value is strongest where cross-sectional imaging has limitations, including pancreatic lesion characterization, subepithelial tumor evaluation, bile duct assessment, mediastinal staging, and tissue acquisition through EUS-guided fine-needle aspiration and fine-needle biopsy.

Demand is supported by the global burden of digestive cancers and complex hepatopancreatobiliary disorders. WHO/IARC GLOBOCAN 2022 estimated 20.0 million new cancer cases and 9.7 million cancer deaths globally, with colorectal, stomach, liver, esophageal, and pancreatic cancers representing major indications connected to advanced endoscopic imaging and staging workflows. In this environment, EUS is moving from a specialist diagnostic tool toward an integrated platform for diagnosis, staging, drainage, and minimally invasive intervention.

Transformative Shifts in the EUS Landscape

The EUS landscape is shifting from diagnostic visualization to image-guided intervention. Linear echoendoscopes, improved ultrasound processors, elastography, contrast-enhanced EUS, and dedicated biopsy needles are enabling more confident lesion assessment and higher-yield sampling, while interventional EUS is expanding the role of endoscopy suites in biliary drainage, pancreatic fluid collection management, and gallbladder drainage for selected patients.

Hospital systems are also prioritizing technologies that shorten care pathways. EUS can reduce diagnostic uncertainty by combining real-time imaging with tissue acquisition in one session, which is important for oncology care pathways that depend on rapid staging and molecular testing. Procurement decisions increasingly consider total episode-of-care value, training requirements, service contracts, scope reprocessing capacity, infection prevention, and compatibility with existing endoscopy, ultrasound, pathology, and electronic reporting infrastructure.

Cumulative Impact of Artificial Intelligence on EUS

Artificial intelligence is beginning to influence endoscopy ultrasound through image interpretation, workflow optimization, quality management, and decision support. The strongest commercial evidence in gastrointestinal endoscopy is currently in AI-assisted colonoscopy for polyp detection, with FDA-cleared and CE-marked computer-aided detection systems demonstrating that AI can be deployed in live endoscopy workflows. EUS is following a more specialized path because image quality, operator technique, lesion heterogeneity, and limited labeled datasets create higher validation barriers.

In EUS, AI research is concentrated on pancreatic cancer differentiation, chronic pancreatitis assessment, subepithelial lesion classification, lymph node characterization, anatomical landmark recognition, and needle-guidance support. The cumulative impact will be greatest where AI improves standardization across operators, reduces missed lesions, supports trainees, and creates structured data for multidisciplinary oncology teams. Adoption will depend on prospective validation, cybersecurity, regulatory clearance, explainable outputs, and integration with electronic health records, picture archiving systems, endoscopy reporting platforms, and hospital data-governance frameworks.

Key Regional Insights Across Global EUS Markets

Asia-Pacific is a high-growth EUS region because of large patient populations, rising cancer screening capacity, expanding tertiary hospitals, and strong demand in China, Japan, South Korea, India, Australia, and ASEAN markets. Japan and South Korea have mature endoscopy ecosystems and deep clinical expertise in upper gastrointestinal and pancreatobiliary procedures, while China and India are expanding access through hospital infrastructure investment, specialist training, and growing oncology referral networks. Australia supports adoption through concentrated advanced endoscopy centers, high clinical governance standards, and established pathways for complex gastrointestinal care.

North America remains a premium EUS market supported by advanced academic centers, complex procedural reimbursement environments, FDA-regulated technology adoption, and extensive use of EUS in pancreaticobiliary and oncology pathways. Europe benefits from guideline-driven practice, cross-border clinical research, structured public procurement, and strong adoption in Germany, France, Italy, Spain, and the United Kingdom. Latin America, the Middle East, and Africa show selective but meaningful growth led by private hospitals, cancer center development, referral-based advanced endoscopy services, and modernization programs in Brazil, Mexico, GCC states, South Africa, and major urban healthcare hubs.

Key Group Insights for EUS Adoption

ASEAN demand is shaped by private hospital investment, medical tourism, rising digestive disease diagnosis, and expanding specialist capacity in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is advancing EUS adoption through specialty hospital expansion, government healthcare modernization, and demand for minimally invasive oncology and hepatopancreatobiliary services, particularly in Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait, where tertiary care investment supports advanced diagnostic and therapeutic endoscopy.

The European Union provides a large regulated EUS market where MDR compliance, clinical evidence, traceability, and procurement transparency influence supplier selection. BRICS markets combine scale with uneven access, making local distribution, clinician training, service responsiveness, and affordability critical in Brazil, Russia, India, China, and South Africa. G7 countries represent high-value innovation markets with mature reimbursement structures, academic research networks, and early adoption of validated digital technologies, while NATO member markets show overlapping demand in Europe and North America for resilient medical technology supply chains, cybersecurity, standardized quality systems, and continuity of critical healthcare equipment access.

Key Country Insights in Endoscopy Ultrasound

The United States leads high-acuity EUS use through academic medical centers, ambulatory endoscopy networks, pancreatic cancer programs, and advanced therapeutic endoscopy services, while Canada emphasizes evidence-based adoption across provincial health systems and structured referral pathways. Mexico and Brazil are the largest Latin American opportunities, supported by private healthcare expansion, specialist referral centers, and demand for advanced diagnostic services in major metropolitan areas.

In Europe, the United Kingdom, Germany, France, Italy, and Spain demonstrate strong procedural expertise, guideline-led adoption, and demand for high-quality biopsy and interventional platforms, while Russia's opportunity is influenced by regional hospital modernization, procurement access, and specialist availability. China, India, Japan, Australia, and South Korea anchor Asia-Pacific: Japan and South Korea are technology-forward endoscopy markets with strong clinical proficiency, China is scaling tertiary capacity and oncology infrastructure, India is expanding specialist access across metropolitan hospital networks, and Australia combines high clinical standards with concentrated advanced endoscopy centers and multidisciplinary cancer care pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation in real-world EUS workflows, including diagnostic yield, adverse events, procedure time, reintervention rates, tissue adequacy, and pathology suitability for molecular testing. Clinical differentiation should be supported by multicenter studies, registry evidence, and peer-reviewed outcomes rather than product claims based only on image quality.

Manufacturers and providers should invest in training programs, simulation, proctoring, and standardized reporting because operator skill remains a major determinant of EUS outcomes. Commercial teams should align product portfolios with service support, scope uptime, infection prevention, needle compatibility, reprocessing capacity, and AI-readiness. Organizations entering emerging markets should pair distribution with clinician education, maintenance capability, and local workflow adaptation to reduce adoption friction and improve long-term utilization.

Research Methodology for EUS Market Analysis

This executive summary is built from a structured market-research approach combining secondary evidence, clinical guideline review, regulatory intelligence, and industry triangulation. Key reference inputs include WHO/IARC cancer burden data, public regulatory databases such as the U.S. FDA, peer-reviewed gastroenterology literature, society guidance from organizations such as ASGE and ESGE, hospital procurement signals, health-system policy documents, and public disclosures related to device regulation and clinical adoption.

The analysis emphasizes cross-validation across demand indicators, installed-base considerations, technology maturity, reimbursement environments, clinical guidelines, regulatory pathways, and regional healthcare infrastructure. Insights are interpreted through clinical, commercial, regulatory, and operational lenses to avoid overreliance on a single data source or unverified market narrative, while excluding market estimation, market sizing, market share, and forecasting assumptions.

Conclusion: EUS Moves Toward Precision GI Care

Endoscopy ultrasound is becoming a core technology in precision gastrointestinal care because it brings imaging, staging, tissue acquisition, and minimally invasive therapy closer to the point of diagnosis. Adoption is supported by cancer burden, demand for faster diagnostic pathways, improved biopsy technologies, and expanding interventional applications in pancreatobiliary and gastrointestinal disease management.

The next competitive phase will be defined by clinical evidence, AI-enabled standardization, workflow integration, infection prevention, training depth, and regional execution. Organizations that combine advanced EUS imaging platforms with service reliability, physician education, validated digital intelligence, and strong operational support will be best positioned in the evolving endoscopy ultrasound market.

Product Code: MRR-4348D129FA94

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Endoscopy Ultrasound Market, by Product

7.1. Forward Viewing
7.2. Linear Array
7.3. Radial Array

8. Endoscopy Ultrasound Market, by Technology

8.1. Contrast Enhancement
- 8.1.1. Microbubble Agents
- 8.1.2. Parameter Quantification
8.2. Elastography
- 8.2.1. Shear Wave
- 8.2.2. Strain
8.3. Mini Probes
8.4. Three D EUS
- 8.4.1. Offline Reconstruction
- 8.4.2. Real Time Three D

9. Endoscopy Ultrasound Market, by Application

9.1. Gastrointestinal Tumors
9.2. Lymph Node Staging
9.3. Pancreatobiliary Diseases
9.4. Submucosal Tumors

10. Endoscopy Ultrasound Market, by End User

10.1. Ambulatory Surgery Centers
10.2. Diagnostic Centers
10.3. Hospitals

11. Endoscopy Ultrasound Market, by Region

11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa

12. Endoscopy Ultrasound Market, by Group

12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO

13. Endoscopy Ultrasound Market, by Country

13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea

14. Competitive Landscape

14.1. Market Concentration Analysis, 2025
- 14.1.1. Concentration Ratio (CR)
- 14.1.2. Herfindahl Hirschman Index (HHI)
14.2. Recent Developments & Impact Analysis, 2025
14.3. Product Portfolio Analysis, 2025
14.4. Benchmarking Analysis, 2025

15. Company Profiles

15.1. Alpinion Medical Systems Co., Ltd.
15.2. B. Braun Melsungen AG
15.3. BK Medical
15.4. Boston Scientific Corporation
15.5. Canon Medical Systems Corporation
15.6. Conmed Corporation
15.7. Cook Medical LLC
15.8. EndoSound, Inc.
15.9. Fujifilm Holdings Corporation
15.10. Hitachi, Ltd.
15.11. Huaco Healthcare Technologies Co., Ltd.
15.12. Johnson & Johnson Services, Inc.
15.13. Medi-Globe GmbH
15.14. Medtronic plc
15.15. Mindray Medical International Limited
15.16. Olympus Corporation
15.17. PENTAX Medical
15.18. Richard Wolf GmbH
15.19. Samsung Medison Co., Ltd.
15.20. Shenzhen Anke High-tech Co., Ltd.
15.21. Siemens Healthineers AG
15.22. Smith & Nephew plc
15.23. SonoScape Medical Corp.
15.24. Teratech Corporation